Tracers / 2-[211At]astato-α-methyl-L-phenylalanine
2-[211At]astato-α-methyl-L-phenylalanine
Also written as 2-[211At]AAMP; [211At]AAMP
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- Radiohalogenated amino acid analogue (alpha-methyl-phenylalanine derivative), LAT1 substrate
- Target / mechanism
- L-type amino acid transporter 1 (LAT1), highly expressed in various human cancers; cellular uptake inhibited by an LAT1-selective inhibitor PMID 32916470
- Clinical application
- Targeted alpha-radionuclide therapy for LAT1-expressing tumours; evaluated in an LAT1-expressing ovarian cancer (SKOV3) tumour-bearing mouse model PMID 32916470
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for 2-[211At]astato-α-methyl-L-phenylalanine, or handle the enquiry for you.
Get in touchNotes
Added stage 29 (2026-09-14): split out of the former 'at211-astato' fragment row. PMID 32916470 ('Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[211At]astato-α-methyl-L-phenylalanine in tumor-bearing model') describes this specific, named compound -- the original 'at211-astato' name was a truncation that dropped '-alpha-methyl-L-phenylalanine' entirely. Prepared from a stannyl precursor per the source abstract; no synthesis run has been parsed into the corpus yet. at211-astato itself was left as-is (kept, not deleted) with its remaining PMID 39596451 (a broader LAT1/At-211 development review) -- see its own Notes.